Rhythm Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was MXN3,691 Mil.
Rhythm Pharmaceuticals's quarterly Total Liabilities
declined
from Sep. 2025 (MXN3,874.13 Mil) to Dec. 2025 (MXN3,784.26 Mil) and
declined
from Dec. 2025 (MXN3,784.26 Mil) to Mar. 2026 (MXN3,691.29 Mil).
Rhythm Pharmaceuticals's annual Total Liabilities
increased
from Dec. 2023 (MXN2,766.57 Mil) to Dec. 2024 (MXN4,749.34 Mil) but then
declined
from Dec. 2024 (MXN4,749.34 Mil) to Dec. 2025 (MXN3,784.26 Mil).
Rhythm Pharmaceuticals Total Liabilities Related Terms
Rhythm Pharmaceuticals Total Liabilities Historical Data
* Premium members only.
The historical data trend for Rhythm Pharmaceuticals's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Rhythm Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of MXN3,691 Mil mean?
Rhythm Pharmaceuticals (MEX:RYTM) has a Total Liabilities of MXN3,691 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Total Liabilities too high?
Rhythm Pharmaceuticals' current Total Liabilities is MXN3,691 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Total Liabilities compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Total Liabilities of MXN3,691 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Total Liabilities is MXN3,691 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Total Liabilities of MXN3,691 Mil. The stock's GF Value™ is MXN1,874.87, compared to a current price of MXN1,866.76 — trading 0.4% below its estimated fair value. The current Total Liabilities is MXN3,691 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Total Liabilities is MXN3,691 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN1,866.76 is trading 0.4% below its estimated GF Value™ of MXN1,874.87.
Key valuation signals for MEX:RYTM:
Total Liabilities: MXN3,691 Mil
GF Value™: MXN1,874.87 vs. price of MXN1,866.76 (0.4% below fair value)
No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score
Get the complete analysis for MEX:RYTM
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RYTM has been successfully added to your 
